Press release
Uterine Fibroids Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight
Request a sample and discover the recent advances in Uterine Fibroids Drugs @ https://www.delveinsight.com/sample-request/uterine-fibroids-pipeline-insight [https://www.delveinsight.com/sample-request/uterine-fibroids-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Uterine Fibroids Pipeline Report
* On February 11, 2026, Shenzhen Kangzhe Biotechnology Co., Ltd . conducted a Phase II Clinical Study to Explore the Efficacy and Safety of Different Doses of CMS-D002 Capsule in Participants With Uterine Fibroids Associated With Menorrhagia.
* On February 02, 2026, Qilu Pharmaceutical Co., Ltd . conducted a study is a phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-designed efficacy and safety study to evaluate 12 weeks of oral daily relugolix 40 mg co-administered with megestrol acetate 1 mg and medroxyprogesterone acetate 2 mg (the treatment group) or 12 weeks of daily oral relugolix 40 mg placebo (the placebo group) followed by 12 weeks of daily oral relugolix 40 mg co-administered with megestrol acetate 1 mg and medroxyprogesterone acetate 2 mg.
* DelveInsight's Uterine Fibroids Pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline Uterine Fibroids drugs.
* The leading Uterine Fibroids Companies such as AbbVie Inc, Addex Therapeutics Ltd, Bayer AG, BioSpecifics Technologies Corp, Dongkook Pharmaceutical Co Ltd, Kissei Pharmaceutical Co Ltd, Myovant Sciences, Ogeda SA, Repros Therapeutics Inc, Takeda Pharmaceutical Company Ltd and others.
* Promising Uterine Fibroids Therapies such as Progenta, Relugolix, Estradiol, Telapristone Acetate, Leuprorelin (GF), Leuprorelin (GF), TAK-385, PGL4001 5 mg and others.
Find out more about Uterine Fibroids Drugs @ Uterine Fibroids Treatment [https://www.delveinsight.com/sample-request/uterine-fibroids-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Uterine Fibroids Overview
Uterine fibroids are benign (not cancer) growths that develop from the muscle tissue of the uterus. They also are called leiomyomas or myomas. The size, shape, and location of fibroids can vary greatly. They may be inside the uterus, on its outer surface or within its wall, or attached to it by a stem-like structure. A woman may have only one fibroid or many of varying sizes. A fibroid may remain very small for a long time and suddenly grow rapidly, or grow slowly over a number of years. Fibroids are most common in women aged 30-40 years, but they can occur at any age. Fibroids occur more often in African American women than in white women. They also seem to occur at a younger age and grow more quickly in African American women
Uterine Fibroids Emerging Drugs
* Linzagolix: Kissei Pharmaceutical
Linzagolix is a novel, orally administered GnRH (gonadotropin releasing hormone) receptor antagonist. Linzagolix acts by binding to and blocking the GnRH receptor in the pituitary gland, ultimately reducing estrogen production by the ovaries. It is currently in phase III stage of development.
* Relugolix: Myovant Sciences
Relugolix is a small molecule, gonadotropin-releasing hormone (GnRH) receptor antagonist, and an oral investigational drug candidate for the treatment of uterine fibroids, endometriosis, and advanced prostate cancer. As a GnRH receptor antagonist, relugolix binds to and blocks the GnRH receptor (GnRHR) in the anterior pituitary gland.Blocking GnRH receptors decreases the release of gonadotropins - luteinizing hormone (LH) and follicle-stimulating hormone (FSH) - thereby decreasing the downstream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men.
* Fezolinetant: Ogeda
Fezolinetant is being investigated as a superior option to gonadotropin-releasing hormone (GnRH) products as fezolinetant reduces levels of the ovarian hormones estrogen and progesterone, but in a non-castrating manner, as would be required for the safe, effective, chronic treatment of uterine fibroids and endometriosis. It is in phase II stage of development.
The Uterine Fibroids Pipeline Report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Uterine Fibroids with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Uterine Fibroids Treatment.
* Uterine Fibroids Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Uterine Fibroids Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Uterine Fibroids market.
Learn more about Uterine Fibroids Drugs opportunities in our groundbreaking Uterine Fibroids research and development projects @ Uterine Fibroids Unmet Needs [https://www.delveinsight.com/sample-request/uterine-fibroids-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Uterine Fibroids Companies
AbbVie Inc, Addex Therapeutics Ltd, Bayer AG, BioSpecifics Technologies Corp, Dongkook Pharmaceutical Co Ltd, Kissei Pharmaceutical Co Ltd, Myovant Sciences, Ogeda SA, Repros Therapeutics Inc, Takeda Pharmaceutical Company Ltd and others.
Uterine Fibroids pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Infusion
* Intradermal
* Intramuscular
* Intranasal
* Oral
* Parenteral
* Subcutaneous
* Topical.
* Molecule Type
Products have been categorized under various Molecule types such as
* Gene therapies
* Small molecule
* Vaccines
* Polymers
* Peptides
* Monoclonal antibodies
* Product Type
Stay informed about how we're transforming the future of Respiratory Disease @ Uterine Fibroids Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/uterine-fibroids-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Uterine Fibroids Pipeline Report
* Coverage- Global
* Uterine Fibroids Companies- AbbVie Inc, Addex Therapeutics Ltd, Bayer AG, BioSpecifics Technologies Corp, Dongkook Pharmaceutical Co Ltd, Kissei Pharmaceutical Co Ltd, Myovant Sciences, Ogeda SA, Repros Therapeutics Inc, Takeda Pharmaceutical Company Ltd and others.
* Uterine Fibroidss Therapies- Progenta, Relugolix, Estradiol, Telapristone Acetate, Leuprorelin (GF), Leuprorelin (GF), TAK-385, PGL4001 5 mg and others.
* Uterine Fibroids Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
* Uterine Fibroids Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Dive deep into rich insights for new Uterine Fibroids Treatments, visit @ Uterine Fibroids Drugs [https://www.delveinsight.com/sample-request/uterine-fibroids-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Uterine fibroids: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Uterine fibroids - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Uterine fibroids Collaboration Deals
* Late Stage Products (Phase III and NDA)
* Linzagolix: Kissei Pharmaceutical
* Relugolix: Myovant Sciences
* Mid Stage Products (Phase II)
* Fezolinetant: Ogeda
* Early Stage Products (Phase I)
* Pre-clinical and Discovery Stage Products
* Inactive Products
* Uterine fibroids Key Companies
* Uterine fibroids Key Products
* Uterine fibroids- Unmet Needs
* Uterine fibroids- Market Drivers and Barriers
* Uterine fibroids- Future Perspectives and Conclusion
* Uterine fibroids Analyst Views
* Uterine fibroids Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=uterine-fibroids-clinical-trial-pipeline-appears-robust-with-25-key-pharma-companies-actively-working-in-the-domain-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/uterine-fibroids-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Uterine Fibroids Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight here
News-ID: 4388943 • Views: …
More Releases from ABNewswire
Pancreatic Cancer Clinical Trial Pipeline Appears Robust With 170+ Key Pharma Co …
DelveInsight's "Pancreatic Cancer Pipeline Insight 2025" report provides comprehensive insights about 170+ companies and 200+ pipeline drugs in Pthe ancreatic Cancer pipeline landscape. It covers the Pancreatic Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pancreatic Cancer Pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download DelveInsight's comprehensive Pancreatic Cancer…
Immune Complex Membranoproliferative Glomerulonephritis Therapeutics Market Size …
DelveInsight's "Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), historical and forecasted epidemiology as well as Immune Complex Membranoproliferative Glomerulonephritis therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Discover the Immune Complex Membranoproliferative Glomerulonephritis New Treatment @ https://www.delveinsight.com/sample-request/immune-complex-membranoproliferative-glomerulonephritis-ic-mpgn-market [https://www.delveinsight.com/sample-request/immune-complex-membranoproliferative-glomerulonephritis-ic-mpgn-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Immune Complex…
CompareForexBrokers achieves B Corporation certification
CompareForexBrokers has been certified as a B Corporation after meeting verified standards of social and environmental performance, transparency and accountability.
MELBOURNE, Australia - February 12, 2026 - CompareForexBrokers [https://www.compareforexbrokers.com/] today confirmed it has been certified as a B Corporation [https://www.bcorporation.net/en-us/find-a-b-corp/company/compare-forex-brokers/] Trademark , following a comprehensive review of its governance, operations and impact across key stakeholder areas.
B Corporation certification is awarded to companies that meet verified standards of social and environmental performance,…
TopMarket.co.il Expands Its Online Electronics Catalog and Customer Services for …
TopMarket.co.il, an established Israeli online electronics retailer founded in 2002, continues expanding its technology catalog while enhancing customer services, nationwide delivery, warranty support, and wholesale options for consumers and businesses.
TopMarket.co.il, a long-established online electronics retailer based in Netanya, continues to expand its multi-category product catalog while strengthening customer service offerings for consumers and businesses across Israel.
Founded in May 2002, TopMarket.co.il began as a small neighborhood computer store [https://www.topmarket.co.il/en/] and repair…
More Releases for Uterine
Uterine Fibroids Symptoms
USA Fibroids Center is here to offer detailed information on https://www.usafibroidcenters.com/blog/uterine-fibroids-symptoms/ and help you discuss the best treatments for uterine fibroids at the clinic.
Find out the best Fibroid Treatment for you!
Treatments for uterine fibroids are accessed in women with problems related to them and show symptoms such as heavy menstrual bleeding, pain or pressure in the pelvis, or infertility and sterility.
…
Bharath Hospital Kottayam Offers Minimally Invasive Treatment for Uterine Fibroi …
Bharath Hospital Kottayam is excited introduce the latest advancement in women's healthcare - the Uterine Fibroid Embolization (UFE) treatment. Uterine fibroids are non-cancerous growths that form in the uterus. They are a common condition among women, especially those of reproductive age. These tumors can vary in size, from small growths to large masses that can distort the shape of the uterus. Although many women with uterine fibroids experience no symptoms,…
Uterine Manipulator Devices Market Report 2018: Segmentation by Type (Donnez Typ …
Global Uterine Manipulator Devices market research report provides company profile for ConMed, Richard Wolf, Bisinger, Planmeca Oy, Ethicon Endosurgery, Cooper Surgical, Hospiiniz International, C. R. Bard and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025,…
Uterine Fibroids Treatment Market : Hysterectomy to Remain Most Preferred Uterin …
The market for uterine fibroids treatment market is fragmented in nature with a high number of players operating in it across the U.S., states a new market research report by Transparency Market Research. The estimated entry of new players and the increasing research and development activities are some of the key factors that are projected to strengthen the competitive scenario of the market throughout the forecast period. The leading players…
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2018 - Research By Ma …
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2018, provides an overview of the Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline landscape.
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers…
Uterine Fibroids Treatment Market: Rising Prevalence of Uterine Fibroids amongst …
The high prevalence of uterine fibroids across the U.S. has created a significant demand for uterine fibroid treatments across the countries. The growing public concern about the occurrence of uterine fibroids, which are also called uterine leiomyoma, have propelled the demand for treatments and solutions to alleviate the pain, excessive bleeding, and pelvic discomfort.
According to the report by Transparency Market Research, the U.S. uterine fibroid treatment market is anticipated to…
